Cambium Bio (ASX: CMB) is advancing Elate Ocular®, its lead biologic candidate for dry eye disease, towards a pivotal Phase 3 trial. The treatment is based on the company’s proprietary fibrinogen-depleted human platelet lysate platform and has received FDA Fast Track designation.
The planned CAMOMILE-2 study will enrol 515 patients with moderate to severe dry eye across Australia and the United States, with co-primary endpoints assessing corneal staining and eye discomfort. Cambium is targeting first patient enrolment in Q4 2026, followed by topline Phase 3 data in Q4 2027 and a Biologics License Application submission in mid-2028.
To hear more about Elate Ocular®, the Phase 3 program and Cambium Bio’s development strategy, watch the full presentation from CEO Karolis Rosickas above.
